Silence Therapeutics plc, a biotechnology company committed to transforming peoples’ lives by “silencing” diseases through precision engineered medicines, will receive a $2.0 million cash payment from Hansoh Pharmaceutical Group Company Limited following the achievement of a second undisclosed milestone related to the first target under the collaboration.
 
“This represents an important milestone in our efforts to advance this program into the clinic with Hansoh,” said Craig Tooman, President and CEO of Silence. “This is an exciting time for Silence and our mRNAi GOLD platform as we continue to advance and expand our pipeline targeting a wide range of genetic diseases.”
 
Silence and Hansoh entered a collaboration in October 2021 to develop siRNAs (short interfering RNAs) leveraging Silence’s proprietary mRNAi GOLD platform for three undisclosed targets. Under the terms of the agreement, Silence has exclusive rights to the first two targets in all territories except the China region. Hansoh has the exclusive option to license rights to those two targets in the Greater China, Hong Kong, Macau and Taiwan, and global rights to the third target.
 
Today’s announcement represents the fourth research milestone payment achieved under the collaboration.